Formulation Document Review
Last reviewed: · Published by FRIDERM Pro (Jinan Xilemei Import and Export Co., Ltd.)
For technical & regulatory procurement
Direct answer: Material names that sound similar are not the same formulation. Before you compare or quote two products, confirm the exact material designation, concentration, and excipients in writing — do not infer composition from a product name or marketing material alone.
Material names that are commonly confused
| Often confused | Why they are not interchangeable |
|---|---|
| PLLA vs. PDLLA | Poly-L-lactic acid (PLLA) and poly-D,L-lactic acid (PDLLA) are different stereochemical forms of polylactic acid with different degradation and biostimulatory profiles. A supplier quoting "polylactic acid" without specifying which isomer has not told you what you are actually buying. |
| PDRN vs. PN | Polydeoxyribonucleotide (PDRN) and polynucleotide (PN) are related but distinct biomaterial classes with different sourcing, purification and regulatory histories in different markets. Treat them as separate materials until a supplier's documentation confirms otherwise. |
| Topical vs. injectable | The same active ingredient name can appear in both topical (external use) and injectable formulations. Route of administration changes the regulatory classification, sterility requirements and intended use — always confirm which one you are being offered. |
What to request before comparing two formulations
- Full material designation (including isomer/derivative where applicable), not just the family name (e.g. "HA" or "PLLA")
- Concentration or fill weight, and whether that figure represents total formulation weight or net active content
- Excipient list, at the level the supplier is able to disclose without breaching their own confidentiality
- Route of administration and packaging format (vial, syringe, twin-vial, etc.)
FRIDERM Pro's own product pages currently flag several open specification questions per SKU (for example, whether a labelled "mg" figure is total powder weight or net active content). We disclose these gaps rather than guess — see each product page's Open questions section, and request the Certificate of Analysis via Quality & Documentation before you rely on a figure commercially.
Formulation confidentiality during due diligence
A manufacturer is not obliged to disclose a full proprietary formulation before a commercial relationship is established. A reasonable due-diligence request focuses on material classification, regulatory documentation and quality evidence rather than a complete recipe — expect an NDA-gated process for deeper formulation detail on a private-label project.
FAQ
Why can't I just compare products by their active-ingredient name?
Because names like "PLLA" or "PDRN" describe a material family, not a specific formulation. Two products naming the same family can differ in isomer, concentration, excipients and manufacturing process. Always request the specific designation and documentation.
Is comparing material names the same as comparing formulations?
No. Material-name comparison is a starting filter, not a substitute for reviewing the actual specification sheet, concentration basis and route of administration for each SKU you are evaluating.
How confidential is a supplier's formulation during pre-sale due diligence?
Expect partial disclosure (material classification, regulatory and quality documentation) before a commercial agreement, with full formulation detail typically reserved for an NDA-gated private-label process.